Icaritin plus TACE for Advanced HCC: Multicenter Cohort Study Results

288 patients with hepatocellular carcinoma and macrovascular invasion were studied across five hospitals from October 2022 to June 2025. The study found Icaritin combined with TACE improved median overall survival to 16.3 months, compared to 13.3 months for TACE alone. This retrospective cohort analysis was authored by Huilin Lu and shared under a CC-BY-4.0 license.

Use Cases

• Compare survival outcomes based on treatment regimen (TACE plus Icaritin vs. TACE alone).
• Identify prognostic factors for overall survival based on ECOG status, AFP levels, and tumor characteristics.
• Analyze disease control rates between different treatment groups.
• Model progression-free survival based on lesion count and other independent predictors.

Strengths

• Data covers 288 patients from a multicenter study across five tertiary hospitals.
• Results include specific median survival figures: 16.3 vs. 13.3 months for OS and 8.5 vs. 7.6 months for PFS.
• Analysis includes multivariate Cox regression identifying independent prognostic factors.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 18.8 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Multicenter retrospective cohort study.

Time Range

October 2022 to June 2025

Freshness

Last updated 2026-05-29 06:03:59